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The present investigation was directed to study the possible chemoprotective activity of orally administered quercetin against
topotecan-induced cyto- and genotoxicity towards mouse somatic cells in vivo. DNA strand breaks, micronuclei formation,
and mitotic activity were undertaken in the current study as markers of cyto- and genotoxicity. Oxidative stress markers such
as intracellular reactive oxygen species generation, lipid peroxidation, and reduced and oxidized glutathione were assessed in
bone marrow as a possible mechanism underlying this amelioration. Quercetin was neither cytotoxic nor genotoxic in mice at
doses tested. Pretreatment of mice with quercetin signiﬁcantly reduced topotecan-induced genotoxicity and cytotoxicity in bone
marrow cells, and these eﬀects were dose dependent. Moreover, prior administration of quercetin ahead of topotecan challenge
ameliorated oxidative stress markers. In conclusion, quercetin has a protective role in the abatement of topotecan-induced cyto-
and genotoxicity in the bone marrow cells of mice that resides, at least in part, on its antioxidant eﬀects. Based on the data
presented, strategies can be developed to decrease the topotecan-induced bone marrow suppression and secondary malignancy in
cancer patients and medical personnel exposing to topotecan.
1.Introduction
Camptothecin,apentacyclicalkaloidoriginallyisolatedfrom
the Chinese plant Camptotheca acuminata by Wall and Wani
in 1996 [1], is one of the most important lead compounds in
anticancer research. The antitumor activity of camptothecin
is thought to be due to its ability to stabilize the reversible
covalentDNAtopoisomeraseIcomplex[2,3],preventingthe
relegation step of the breakage/rejoining reaction mediated
by the enzyme. The net result is that the drug causes
fragmentation of chromosomal DNA, cell death, extensive
sister chromatid exchange, and chromosomal aberrations
[4, 5]. Elucidation of the speciﬁc target and mechanisms of
camptothecin have stimulated intensive eﬀorts to identify
novel analogues that overcome the drawbacks of the natural
camptothecin molecule, which include low solubility in
water; severe and unpredictable toxicity, including hemor-
rhagic cystitis; reversibility of the drug-target interaction;
lactone instability; drug resistance. One of the initial major
strategies in this regard has been to improve the solubility
of the natural camptothecin by chemical modiﬁcation [6].
This approach has produced diﬀerent series of water-
soluble analogues or water-soluble prodrugs, among which
topotecan (TPT) and irinotecan are the most successful.
The two camptothecin analogues, TPT and irinotecan,
have received FDA approval for the clinical treatment of
the ovarian cancer and small cell lung cancer [7, 8]a n d
refractory colorectal cancers [9, 10], respectively. Studies
focused on these two drugs have demonstrated mechanistic
diﬀerences between them related to the cytotoxic potency
and the stability of the DNA-topoisomerase I cleavable
complexes [11]. Consequently, this diﬀerential action could
inﬂuencenotonlyformationofstrandbreaksduringreplica-
tion but also the likelihood of cell killing and genetic toxicity
of these new anticancer agents. Indeed, full therapeutic
eﬃcacy of these drugs is limited due to the development
of acquired drug resistance by the cancer cells and various
side eﬀects in the treated patients, including damages of
the normal cells which may lead to the development of
secondary tumors. After application of topoisomerase I
inhibitors, damage to DNA may result as DNA fragmenta-
tion,chromosomalbreaks,andmicronuclei(MN)formation2 Oxidative Medicine and Cellular Longevity
causing genotoxicity and may lead to carcinogenesis. In
animals, TPT is a somatic cell mutagen capable of inducing
chromosome aberrations [12]. Follow-up studies of patients
who received camptothecins containing regimens revealed
an increased incidence of hyperdiploidy and deletion of
chromosome 1 [13]. These eﬀects can develop resistance to
these therapeutic agents or may lead to the development of
secondary tumours. These have prompted the removal of
these highly eﬀective agents from some treatment regimens.
In clinical therapy, to increase drug eﬃcacy and decrease
the adverse reactions by antitumor agents, it is necessary to
combine other drugs [14]. Experimental observations have
shownthat some ﬂavonoids are ableto enhancethe cytotoxic
action of the chemotherapeutic drugs without damaging
normal cells [15]. Consistent with these notions, quercetin,
a polyphenolic compound widely distributed in food of
plant origin, has been reported to have antitumor eﬀects
against several cancer cells [16, 17]. The antitumor eﬀects
of quercetin have been reported to induce cell growth
inhibition and apoptosis in variety of tumor cells [18].
Quercetin has also been shown in vitro to increase the con-
centration of DNA topoisomerase II inhibiters, doxorubicin,
and daunorubicin in some multidrug-resistant cancer cell
lines [19]. Moreover, previous reports demonstrated that
quercetinincreases the growth inhibitory eﬀectof TPTinthe
treatment of human breast cancer cells [20]. Enhancements
of oral bioavailability and reducing gastrointestinal toxicity
of irinotecan by quercetin have been also reported [21].
Therefore, the combination of camptothecins with quercetin
might be of therapeutic beneﬁt. However, the inﬂuence of
quercetin on TPT-induced cyto- and genotoxicity in non-
tumor cells in vivo has not been reported yet.
Considering the widespread use of TPT in clinical
oncology and the ability of quercetin to improve the ther-
apeutic outcome from TPT prompted to investigate whether
quercetin in combination with TPT can ameliorate TPT-
induced cyto- and genotoxicity in mice normal tissues. The
bone marrow DNA strand breaks, the scoring of MN, and
mitotic activity were undertaken in the current study as
markers of cyto- and genotoxicity. Oxidative stress markers
such as bone marrow reactive oxygen species (ROS), lipid
peroxidation, reduced glutathione (GSH), and oxidized
glutathione (GSSG) levels were assessed as a possible mecha-
nism underlying this amelioration.
2. Results
2.1. Eﬀect of Quercetin on TPT-Induced DNA Strand Breaks.
The results of alkaline comet assay are shown in Table 1.
Quercetin treatment did not exhibit any signiﬁcant diﬀer-
ence in the level of tail moment, tail length, tail DNA,
and olive tail moment compared to the solvent control at
either dose tested. The positive control cyclophosphamide
signiﬁcantly increases the level of all measured parameters
compared to the control group (P<0.01). The results
revealed that TPT when given at a single dose of 0.5
or 1mg/kg causes signiﬁcant increase in the level of all
measured parameters in comparison to those of the solvent
control group. However, when pretreatment of diﬀerent
doses of quercetin was given prior to TPT treatment,
decreased rates of DNA strand breaks were observed and the
higher dose of quercetin gave more eﬀective reduction in all
measured parameters.
2.2. Eﬀect of Quercetin on TPT-Induced MNPCE and Bone
Marrow Suppression. The results of the micronucleus test are
presented in Table 2. The frequency of MNPCE in the pos-
itive control mutagen cyclophosphamide was signiﬁcantly
higher when compared to the solvent control group (P<
0.01). Similarly, TPT at a single dose of 0.5 or 1mg/kg
signiﬁcantly increased the frequency of MNPCE (P<0.01).
Moreover, the mitotic index was signiﬁcantly decreased
after treatment with TPT compared to the solvent control
group. Quercetin treatment did not exhibit any signiﬁcant
diﬀerence in the frequency of MNPCE compared to the
solvent control at both tested doses. In addition, quercetin
was not cytotoxic to the bone marrow at the tested doses
level. Pretreatment with quercetin was found to signiﬁcantly
decrease the frequency of MNPCE specially at the higher
dose of quercetin as compared to the values obtained after
treatment with TPT alone. The reduction of mitotic index
induced by TPT was found to be restored by pretreatment
with the higher dose of quercetin.
2.3. Eﬀect of Quercetin on TPT-Induced Oxidative Stress. The
eﬀect of quercetin on the TPT-induced oxidative stress was
assessed by measuring bone marrow ROS accumulation,
MDA content, GSH, and GSSG levels. Bone marrow ROS
production was evaluated by determining the ﬂuorescent
intensity of DCF. As shown in Figure 1, DCF ﬂuorescence
level did not show signiﬁcant variation after treatment
of mice with quercetin at 100mg/kg as compared to the
solvent control. The DCF ﬂuorescence level in mice treated
with 1mg/kg TPT was signiﬁcantly increased by about 1.7-
folds as compared to the control animals (P<0.05).
However, TPT-induced production of DCF ﬂuorescence was
profoundly abrogated by quercetin and decreased to the level
signiﬁcantly diﬀerent from the level of DCF ﬂuorescence in
animals treated with TPT alone (P<0.05).
As shown in Figure 2, no signiﬁcant change in MDA
content was observed in bone marrow cells after quercetin
treatment in a dose of 100mg/kg compared to the control.
The MDA content in mice treated with 1mg/kg TPT was
signiﬁcantly increased (P<0.01). The TPT-induced MDA
formation was abrogated by quercetin and decreased to the
level signiﬁcantly diﬀerent from the level of MDA in the
TPT treated alone (P<0.01). As shown in Figure 3,b o n e
marrow GSSG and GSH levels did not show any signiﬁcant
variation in 100mg/kg quercetin-treated animals compared
to the solvent control. The GSH level observed in 1mg/kg
TPT-treated animals was signiﬁcantly decreased, together
with increase in GSSG level as compared to the control
group (P<0.01); so that GSH/GSSG ratio signiﬁcantly
decreased, indicating increased oxidative stress (P<0.05)
(Figure 4). Animals pretreated with quercetin showed aOxidative Medicine and Cellular Longevity 3
Table 1: DNA strand breaks in bone marrow of mice after treatment with quercetin and/or topotecan (TPT) or cyclophosphamide (mean
± SD).
Treatment groups
(mg/kg)
Tail moment
(arbitrary unit)
Tail DNA
(%)
Tail length
(µm)
Olive tail moment
(arbitrary units)
Control 2.32 ± 0.40 6.78 ± 1.12 16.0 ± 4.84 5.18 ± 1.52
Quercetin (50) 2.68 ± 0.82 6.56 ± 1.67 14.4 ± 5.22 4.34 ± 0.89
Quercetin (100) 2.12 ± 0.35 6.62 ± 2.18 15.2 ± 5.40 3.40 ± 1.11
TPT (0.5) 7.12 ± 1.83∗∗ 18.2 ± 3.07∗∗ 35.0 ± 9.38∗ 12.4 ± 3.28∗
Quercetin (50) + TPT (0.5) 3.98 ± 1.29a 10.2 ± 1.95b 24.4 ± 5.22 7.02 ± 1.53a
Quercetin (100) + TPT (0.5) 2.64 ± 0.82b 7.9 0 ± 2.57b 16.8 ± 4.32b 5.12 ± 1.66b
TPT (1) 13.2 ± 2.27∗∗ 22.5 ± 4.42∗∗ 50.0 ± 6.44∗∗ 18.0 ± 2.51∗
Quercetin (50) + TPT (1) 9.54 ± 1.82 14.6 ± 3.54a 37.6 ± 4.27a 10.9 ± 3.4a
Quercetin (100) + TPT (1) 4.28 ± 1.52b 11.3 ± 3.90b 22.8 ± 6.72b 6.88 ± 1.25b
Cyclophosphamide 40 23.9 ± 4.57# 26.0 ± 6.17# 64.2 ± 6.76# 14.58 ± 1.93#
∗P < 0.05 and ∗∗P < 0.01 versus control (Kruskal-Wallis test followed by Dunn’s multiple comparisons test). aP < 0.05 and bP < 0.01 versus the
corresponding TPT alone; #P < 0.01 versus control (Mann-Whitney U test).
Table 2: Frequency of MNPCE and mitotic activity (% PCE) in
bone marrow of mice treated with quercetin and/or topotecan
(TPT) or cyclophosphamide (mean ± SD).
Treatment groups
(mg/kg)
%M N P C E
(mean ± SD)
%P C E
(mean ± SD)
Control 0.36 ± 0.11 48.8 ± 1.78
Quercetin (50) 0.32 ± 0.08 48.2 ± 2.15
Quercetin (100) 0.30 ± 0.10 48.4 ± 1.81
TPT (0.5) 1.68 ± 0.24∗∗ 41.6 ± 3.43∗
Quercetin (50) + TPT (0.5) 0.96 ± 0.23b 45.8 ± 2.77
Quercetin (100) + TPT
(0.5) 0.58 ± 0.13b 47.4 ± 2.40b
TPT (1) 2.62 ± 0.54∗∗ 39.6 ± 2.19∗
Quercetin (50) + TPT (1) 1.90 ± 0.48 44.0 ± 5.78
Quercetin (100) + TPT (1) 0.72 ± 0.14b 47.6 ± 2.60b
Cyclophosphamide 40 2.06 ± 0.43# 42.2 ± 2.58#
∗P < 0.05 and ∗∗P < 0.01 versus control (Kruskal-Wallis test followed by
Dunn’smultiplecomparisonstest). bP < 0.01versusthecorrespondingTPT
alone; #P < 0.01 versus control (Mann-Whitney U test).
signiﬁcant increase in GSH level over the 1mg/kg TPT-
treatedgroupandincreasedtothelevelsigniﬁcantlydiﬀerent
from the level of GSH in the TPT-treated alone (P<0.01).
The GSSG level was also signiﬁcantly decreased in quercetin
pretreated animals compared to TPT-treated group (P<
0.05). Consequently, the GSH/GSSG ratio was increased in
quercetin pretreated animals and was statistically signiﬁcant
when compared to the TPT-treated mice (P<0.01).
3. Discussion
The objective of the current investigation is to determine
whether nontoxic doses of the bioﬂavonoid quercetin, a
strong antioxidant present in the human diet, have inﬂuence
on the cyto- and genotoxicity induced by the anticancer
topoisomerase-I inhibitor, TPT, on mice bone marrow cells
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Figure 1: Eﬀects of quercetin (100mg/kg) on topotecan (TPT;
1mg/kg)-induced generation of intracellular reactive oxygen
species in the bone marrow cells of mice (mean ± SD).
∗P < 0.05
versus control (Kruskal-Wallis test followed by Dunn’s multiple
comparisons test), aP < 0.05 versus TPT alone (Mann-Whitney U
test).
in vivo. The positive control mutagen cyclophosphamide
was used in this study, and this compound produced the
expected responses. The results of cyclophosphamide were
in the same range as those of the earlier studies [22, 23].
These data conﬁrmed the sensitivity of the experimental
protocol followed in the detection of DNA damaging eﬀects.
The current study demonstrates that quercetin was neither
cytotoxic nor genotoxic at the doses tested. Moreover, it is
able to protect mouse bone marrow cells against the TPT-
induced cyto- and genotoxicity. These results corroborate
earlier studies, where oral administration of quercetin did
not cause DNA damage in the bone marrow cells [24–26].
It was concluded that TPT is a somatic cell cytotoxic
and genotoxic. It induced a dose- and time-dependent
increases in the percentage of MNPCE and chromosome
aberrations in mouse bone marrow after treatment with
single doses of TPT [12]. Centromere labelling (FISH
assay with the pancentromeric minor DNA probe) showed
that about 48% of TPT-induced MN were centromere4 Oxidative Medicine and Cellular Longevity
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Figure 2: Eﬀects of quercetin (100mg/kg) and/or topotecan (TPT;
1mg/kg) on bone marrow lipid peroxidation level (MDA) in mice
(mean ± SD).
∗∗P < 0.01 versus control; bP < 0.01 versus
TPT alone (one way ANOVA and post hoc Tukey-Kramer multiple
comparison test).
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Figure 3: Eﬀects of quercetin (100mg/kg) and/or topotecan
(TPT; 1mg/kg) on bone marrow oxidized glutathione (GSSG) and
reduced glutathione (GSH) levels in mice (mean ± SD).
∗P < 0.05,
∗∗P < 0.01 versus control; aP < 0.05, bP < 0.01 versus TPT alone
(onewayANOVAandposthocTukey-Kramermultiplecomparison
test).
negative, demonstrating that TPT induces not only chro-
mosome loss but also DNA strand breaks [27]. Both the
aneugenic (chromosome loss) and clastogenic (DNA strand
breaks) potential of this drug can lead to the development of
secondary tumours and abnormal reproductive outcomes.
In agreement with the above-cited report, the present
experiment showed that the exposure to TPT caused sig-
niﬁcant increase in the bone marrow DNA strand breaks
and MN frequencies as compared to the values obtained
aftertreatmentwiththesolventcontrol.Prioradministration
of quercetin ahead of TPT challenge ameliorated these
genotoxic markers and clearly suggests the protective role
of quercetin on TPT’s genotoxic potentials. The genotoxic
protection was also directly correlated with mitotic activity
asanobviousprotectionwasnotedwithquercetinpretreated
animals when bone marrow suppression was examined
at interphase stage, where, reductions in TPT-induced
myelosuppression in mice pretreated with quercetin were
observed. Moreover, the protection aﬀorded by quercetin
revealed that quercetin could exert dose-dependent anti-
cytogenotoxic eﬀects. In fact, the ability of quercetin to
Control Quercetin TPT Quercetin +
TPT
0
2
4
6
8
G
S
H
/
G
S
S
G
r
a
t
i
o
Groups
∗
b
Figure 4: Eﬀects of quercetin (100mg/kg) and/or topotecan (TPT;
1mg/kg) on mouse bone marrow reduced and oxidized glutathione
(GSH/GSSG) ratio (mean ± SD).
∗P < 0.05 versus control
(Kruskal-Wallis test followed by Dunn’s multiple comparisons test),
bP < 0.01 versus TPT alone (Mann-Whitney U test).
confer marked protection against diﬀerent toxic chemical
agents has been described. Quercetin mediated inhibition of
bacterial mutagenicity induced by diﬀerent mutagens [28,
29] and mouse clastogenicity induced by the chemothera-
peutic agent; cisplatin has been reported [26].
The exact mechanism by which quercetin protected
against TPT-induced cyto- and genotoxicity in bone marrow
cells is not well known. One possible explanation for the
protection against cyto- and genotoxicity is that simulta-
neous treatment with quercetin would allow interception
of free radicals generated by TPT before they reach DNA
and induce cyto- and genotoxicity. In the present work, in
order to evaluate whether the observed anti-cytogenotoxic
eﬀect was due to an enhancement of the scavenging of free
radicals generated by TPT, oxidative stress markers such
as ROS accumulation, lipid peroxidation, and GSH/GSSG
ratio were evaluated after the animals were treated with
TPT, compared with the prior treatment with quercetin and
the solvent control animals. The present study demonstrates
that quercetin pretreatment reduced the TPT-induced bone
marrowROSaccumulationlipid peroxidation andprevented
the reduction in GSH/GSSG ratio signiﬁcantly.
TPT is able to generate ROS, which causes damage to
cellular genome and also the cell membrane leading to lipid
peroxidation[30,31].Theendproductsoflipidperoxidation
also interact with DNA causing DNA strand breaks that in
turn develop into chromosomal breaks. These chromosomal
breaks may appear as MN in the daughter cell after the
ﬁrst cell division. In agreement with the above-cited reports,
the present experiment showed that TPT treatment caused
signiﬁcant increases in ROS and lipid peroxidation levels
and quercetin pretreatment reduced the TPT-induced ROS
and lipid peroxidation signiﬁcantly. Quercetin is known as
a potent free radical scavenger, capable of inhibiting lipid
peroxidation in in vitro and in vivo systems [25, 26, 32].
It has been reported that TPT induces a decrease in
the antioxidant enzyme activities in healthy rabbit liver
[30, 31]. This can induce cyto- and genotoxicity through
the failure of the antioxidant defence mechanisms, since
antioxidants are able to protect nontumor cells acting as
antigenotoxins without compromising the antineoplasticOxidative Medicine and Cellular Longevity 5
eﬀects. The increased GSH and GSH/GSSG levels suggest
that protection by quercetin may be mediated through the
modulation of cellular antioxidant levels. These observations
conﬁrm earlier studies in which quercetin was reported
to elevate GSH, glutathione peroxidise and superoxide
dismutase and to reduce lipid peroxidation [24–26]. A
decrease in bone marrow GSH/GSSG ratio noted after TPT-
treatment could lead to less protective mechanism in bone
marrow cells and thereby developing more TPT induced
bonemarrowtoxicity.However,thegroupofmicepretreated
withquercetinshowingdecreasedcyto-andgenotoxiceﬀects
and a signiﬁcant increase in the bone marrow GSH/GSSG
ratio suggests the deﬁnite signiﬁcance of GSH also. It could
be the elevated level of GSH to protect the cells against TPT-
induced cyto- and genotoxicity.
Insummary,acriticalpointofthisstudyisthepossibility
that there may be a therapeutic window for the use of TPT in
combination with quercetin, so that its harmful side eﬀects
in normal cells are minimized. The deleterious eﬀects of TPT
might be, at least in part, mediated by an oxidative stress
mechanism that may be prevented or reduced by radical
scavengers. TPT has a direct eﬀect on DNA topoisomerase
I, an important component of its antitumor activity, and
this will be unchanged by any manipulations that alter
the redox reaction. The improvement in mitotic activity of
bone marrow cells of animals pretreated with quercetin in
TPT toxicity may focus attention on the beneﬁcial eﬀect of
quercetintoovercomeoneofthemostseriousproblemswith
cancerchemotherapy,whichisthebonemarrowsuppression
and related immunosuppression. Quercetin was eﬀective in
reducing cyto- and genotoxicity induced by TPT in bone
marrow cells and may possibly decrease the risk of secondary
tumors in cells that were not originally neoplastic. The
protective eﬀect of quercetin could be possibly ascribed to its
radical scavenger eﬀect that modulated the changes induced
by TPT. Based on the data presented here, strategies can
be developed to decrease the deleterious eﬀects of TPT in
normal cells by using quercetin.
4.MaterialsandMethods
4.1.Animals. AdultmaleSwissalbinomiceweighing25–30g
(10–12 weeks old) were obtained from Experimental Animal
Care Center, College of Pharmacy, King Saud University.
The animals were maintained under standard conditions of
humidity,temperature(25 ±2◦C),andlight(12-hlight/12-h
dark).Theywerefedwithastandardmicepelletdietandhad
free access to water. All experiments on animals were carried
out according to the guidelines of the Animal Care and Use
Committee at College of Pharmacy, King Saud University.
4.2. Drugs and Chemicals. Quercetin (Sigma Chemical Co,
St. Louis, USA) was administered by gavage in propylene
glycol as a vehicle. Gavages administrations were made 24h
and 1h prior to the TPT intraperitoneal injection. Control
animals were given propylene glycol vehicle only. Quercetin
was administered at the doses level of 50 and 100mg/kg.
Upon conversion of animal dose to the equivalent human
dose, a dose of 100mg/kg quercetin in mice was found to
be corresponding to 8.1mg/kg in humans. Accordingly, for
an average person weighing 60kg, 486mg quercetin would
be needed. National dietary record-based cohort assessments
of the intake of quercetin from the habitual diet indicated
daily levels of quercetin as high as 200–500mg may be
attained by high-end consumers of fruits and vegetables,
especially in cases where the individuals consume the peel
portionofquercetin-richfruitsandvegetables,suchastoma-
toes, apples, and onions [33]. TPT and cyclophosphamide
(Sigma-Aldrich, St. Louis, USA) were dissolved in saline
immediately before use. The doses of TPT (0.5 and 1mg/kg)
were selected on the basis of literature data [12, 27]. All other
chemicals were of the ﬁnest analytical grade.
4.3. Experimental Protocol. Male mice were acclimatized for
2 days and divided into 10 groups consisting of 5 mice
e a c h ,s e tu pa sf o l l o w s :G r o u p1 :m i c ew e r es e r v e da sa
control group and treated daily with the vehicle only for
two consecutive days; Groups 2 and 3: mice were treated
with quercetin in a dose of 50 or 100mg/kg, respectively,
once a day, for two consecutive days; Group 4: mice were
injected with a single dose of 0.5mg/kg TPT alone; Groups
5 and 6: mice were treated with quercetin at a dose of 50 or
100mg/kg/day, respectively, once a day, for two consecutive
days and 0.5mg/kg of TPT was administrated on day 2, 1
hour after quercetin exposure; Group 7: mice were injected
with a single dose of 1mg/kg TPT alone; Groups 8 and
9: mice were treated with quercetin at a dose of 50 or
100mg/kg/day, respectively, once a day, for two consecutive
days and 1mg/kg of TPT was administrated on day 2, 1
hour after regular quercetin exposure; Group 10: mice were
injected with a single dose of 40mg/kg cyclophosphamide
and used as a positive control mutagen.
4.4. Detection of DNA Strand Breaks. Mice were sacriﬁced
by cervical dislocation 24h after TPT treatment, and the
bonemarrowcellsfromonefemurwerecollected.Single and
double DNA strand breaks were studied by alkaline single
cell gel electrophoresis (alkaline comet assay) according to
the guidelines of Tice et al. [34], with slight modiﬁcations
as previously described [23]. The slides were stained with
ethidium bromide (20µg/mL) and studied using a ﬂuores-
cent microscope (Nikon, Japan) equipped with appropriate
ﬁlters. Fifty individual cells were selected for calculations
f o re a c ha n a l y s i s ;a l le x p e r i m e n t sw e r ec a r r i e do u ta tl e a s t
three times, each with two parallel slides per data point.
Single cells were analyzed with TriTek CometScore version
1.5 software (Figure 5). The parameters studied to access the
DNA damage were the tail moment (arbitrary units), tail
D N A( % ) ,t a i ll e n g t h( µm), and olive moment (arbitrary
units).
4.5. Bone Marrow Micronucleus Test. The remaining femora
from the same animals used for the alkaline comet assay
were used for estimation of MN frequencies and mitotic
activity. Bone marrow smears were done, and the slides were
stained with May-Gruenwald/Giemsa solutions as described6 Oxidative Medicine and Cellular Longevity
Figure 5: Representative analysis of a ﬂuorescent comet image of a
m o u s eb o n em a r r o wc e l l .
earlier [35]. Per animal, 1,000 polychromatic erythrocytes
(PCE) were blindly scored microscopically for the presence
of MN. In addition, the number of PCEs among 1,000 nor-
mochromatic erythrocytes (NCE) per animal was recorded
to evaluate bone marrow suppression, mitotic activity was
calculated as %PCE = [PCE/(PCE + NCE)] × 100.
4.6. Measurement of Oxidative Stress Markers. To study
the eﬀect of quercetin on the oxidative DNA damage in-
duced by TPT, animals were treated as in groups 1, 3,
7, and 9. Mice were sacriﬁced by cervical dislocation
24h after TPT treatment, and the bone marrow cells
from both femurs were collected for estimation of ROS
accumulation, lipid peroxidation, GSH, and GSSG levels.
The generation of intracellular ROS was evaluated based
on the intracellular peroxide-dependent oxidation of 2 ,7 -
dichlorodihydroﬂuorescein diacetate (DCFH-DA) to form
a ﬂuorescent compound, 2 ,7 -dichloroﬂuorescein (DCF),
with modiﬁcations as previously described [36]. The bone
marrow cells were collected in tubes containing 1.5mL
fetal calf serum then centrifuged and washed with cold
PBS (pH 7.4). The bone marrow cells were harvested by
centrifugation, washed twice with cold PBS, and ﬁnally
resuspendedinPBS.200µLbonemarrowcells(2×105)were
incubated with 200µL of DCFH-DA (0.4nM) for 60min at
37◦C in dark. The ﬂuorescence intensity was monitored with
a FLUOstar OMEGA microplate reader (BMG LABTECH
Ltd., Germany) at an excitation wavelength of 485nm and
an emission wavelength of 520 nm. Results were expressed as
fold of control.
Malonodialdehyde (MDA) generated by lipid peroxida-
tion was quantiﬁed in the bone marrow cells according
to the method of Ohkawa et al. [37], based on thio-
barbituric acid (TBA) reactivity. The MDA levels of the
samples were calculated from the standard curve using the
1,1,3,3-tetramethoxypropane as the standard and expressed
as µmol/g protein. GSH was assayed with 5,5 -dithiobis
(2-nitrobenzoic acid) (DTNB) according to the protocol
described by Ellman [38]. GSSG was assayed with DTNB,
glutathione reductase, and NADPH as described previously
[39]. The concentrations of GSH and GSSG were calculated
from standard curves that were obtained from freshly
prepared standard solutions of GSH and GSSG, respectively,
a n de x p r e s s e da sµmol/g protein. The value obtained for
GSH was divided by the GSSG value to get the GSH/GSSG
ratio. Protein measurement was carried out by the method
of Lowry et al. [40], using bovine serum albumin as the
standard.
4.7. Statistical Analysis. Data were expressed as the mean
± standard deviation (SD) of the means. The analyzed
parameters were tested for homogeneity of variance and
normality and were found to be normally distributed. The
data were, therefore, analyzed by employing nonparametric
tests, Mann-Whitney U-test, and Kruskal-Wallis test fol-
lowed by Dunn’s multiple comparisons test or analysis of
variance, ANOVA, followed by Tukey-Kramer for multiple
comparisons. Results were considered signiﬁcantly diﬀerent
if the P value was < 0.05.
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